Product Description
Mechanisms of Action: CRFR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Generalized anxiety disorder
Phase 2: Depressive Disorder, Major|Alcoholism|Alcohol-Related Disorders|Irritable Bowel Syndrome
Phase 1: Taste Disorders|Hypertension|Overweight|Weight Loss
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01656577 |
12-DA-N475 | P1 |
Terminated |
Hypertension|Overweight|Weight Loss|Taste Disorders |
2015-09-01 |
2019-03-19 |
Treatments |
|
NCT01227980 |
11-AA-0010 | P2 |
Completed |
Alcoholism|Alcohol-Related Disorders |
2014-07-01 |
2019-03-22 |
Treatments |
|
NCT00135421 |
CN148-007 | P2 |
Completed |
Depressive Disorder, Major |
2007-10-01 |
2019-03-21 |
Treatments |
|
NCT00399438 |
CN148-013 | P2 |
Completed |
Irritable Bowel Syndrome |
2007-10-01 |
2019-03-21 |
Treatments |
|
NCT00481325 |
CN148-015 | P3 |
Completed |
Generalized anxiety disorder |
2008-03-01 |
2019-03-21 |
Treatments |